PTC Therapeutics, Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
PTC Therapeutics, Inc. (PTCT) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $119.48 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-22.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2022-02-22
- PTC Therapeutics, Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-12-31 was -$7.00K.
- PTC Therapeutics, Inc. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2019-09-30 was $119.49M.
- PTC Therapeutics, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2019 was $119.48M.
- PTC Therapeutics, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2015 was $55.75M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $119.48M derived: sum of 2 quarters · filed 2022-02-22 | $119.48M 10-K · filed 2022-02-22 | ||
| 2019-09-30 | $119.49M 10-Q · filed 2020-10-29 | $119.49M 10-Q · filed 2020-10-29 | |||
| 2015-12-31 | $55.75M 10-K · filed 2018-03-06 | $57.54M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |